공시 • Mar 05
UniPharma Co., Ltd., Annual General Meeting, May 18, 2026 UniPharma Co., Ltd., Annual General Meeting, May 18, 2026, at 10:00 Taipei Standard Time. Location: 3 floor no,17 ln.171, sec.2 chiu tsung rd., neihu district, taipei city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$91m revenue, or US$2.9m). Market cap is less than US$100m (NT$443.8m market cap, or US$14.1m). New Risk • Sep 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Revenue is less than US$5m (NT$91m revenue, or US$3.0m). Market cap is less than US$100m (NT$511.2m market cap, or US$17.0m). Reported Earnings • May 22
Full year 2024 earnings released: NT$0.70 loss per share (vs NT$0.61 loss in FY 2023) Full year 2024 results: NT$0.70 loss per share (further deteriorated from NT$0.61 loss in FY 2023). Revenue: NT$93.5m (down 9.5% from FY 2023). Net loss: NT$24.8m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (NT$100m revenue, or US$3.0m). Market cap is less than US$100m (NT$504.1m market cap, or US$15.2m). 공시 • Mar 24
UniPharma Co., Ltd., Annual General Meeting, Jun 18, 2025 UniPharma Co., Ltd., Annual General Meeting, Jun 18, 2025. Location: 3 floor no,17 ln.171, sec.2 chiu tsung rd., neihu district, taipei city Taiwan New Risk • Feb 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$100m revenue, or US$3.0m). Market cap is less than US$100m (NT$523.6m market cap, or US$16.0m). New Risk • Jun 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Revenue is less than US$5m (NT$103m revenue, or US$3.2m). Market cap is less than US$100m (NT$461.5m market cap, or US$14.2m). Reported Earnings • Apr 25
Full year 2023 earnings released: NT$0.61 loss per share (vs NT$0.18 loss in FY 2022) Full year 2023 results: NT$0.61 loss per share (further deteriorated from NT$0.18 loss in FY 2022). Revenue: NT$103.2m (down 19% from FY 2022). Net loss: NT$21.8m (loss widened 238% from FY 2022). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 25
Full year 2023 earnings released: NT$0.61 loss per share (vs NT$0.18 loss in FY 2022) Full year 2023 results: NT$0.61 loss per share (further deteriorated from NT$0.18 loss in FY 2022). Revenue: NT$103.2m (down 19% from FY 2022). Net loss: NT$21.8m (loss widened 238% from FY 2022). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. 공시 • Apr 12
UniPharma Co., Ltd., Annual General Meeting, Jun 25, 2024 UniPharma Co., Ltd., Annual General Meeting, Jun 25, 2024. New Risk • Feb 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$124m revenue, or US$3.9m). Market cap is less than US$100m (NT$475.7m market cap, or US$15.1m). New Risk • Oct 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Revenue is less than US$5m (NT$124m revenue, or US$3.8m). Market cap is less than US$100m (NT$568.0m market cap, or US$17.5m). Reported Earnings • Apr 22
Full year 2022 earnings released: NT$0.18 loss per share (vs NT$2.11 loss in FY 2021) Full year 2022 results: NT$0.18 loss per share (improved from NT$2.11 loss in FY 2021). Revenue: NT$128.1m (up 22% from FY 2021). Net loss: NT$6.45m (loss narrowed 91% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings. Reported Earnings • Aug 15
First half 2022 earnings released: EPS: NT$0.07 (vs NT$0.61 loss in 1H 2021) First half 2022 results: EPS: NT$0.07 (up from NT$0.61 loss in 1H 2021). Revenue: NT$54.5m (up 18% from 1H 2021). Net income: NT$2.52m (up NT$23.9m from 1H 2021). Profit margin: 4.6% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • Apr 18
Full year 2021 earnings released: NT$2.11 loss per share (vs NT$1.57 loss in FY 2020) Full year 2021 results: NT$2.11 loss per share (down from NT$1.57 loss in FY 2020). Revenue: NT$105.4m (down 24% from FY 2020). Net loss: NT$74.4m (loss widened 34% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has remained flat, which means it is well ahead of earnings. 공시 • Apr 02
UniPharma Co., Ltd., Annual General Meeting, Jun 21, 2022 UniPharma Co., Ltd., Annual General Meeting, Jun 21, 2022. Reported Earnings • Apr 25
Full year 2020 earnings released: NT$1.57 loss per share (vs NT$0.71 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: NT$138.6m (down 10% from FY 2019). Net loss: NT$55.4m (loss widened 121% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 18
New 90-day low: NT$11.80 The company is down 31% from its price of NT$17.15 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period. Is New 90 Day High Low • Jan 06
New 90-day low: NT$14.90 The company is down 25% from its price of NT$20.00 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period. Is New 90 Day High Low • Dec 10
New 90-day low: NT$15.95 The company is down 34% from its price of NT$24.10 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 12% over the same period. Is New 90 Day High Low • Nov 12
New 90-day low: NT$16.35 The company is down 23% from its price of NT$21.35 on 14 August 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.